A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Lo… (NCT02459457) | Clinical Trial Compass
CompletedPhase 3
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
China321 participantsStarted 2015-07-01
Plain-language summary
The purpose of this study is to determined the best scheme in paclitaxel and cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy for patients with local advanced esophageal Squamous Cell Carcinoma.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. Clinical stages II, III or IVa based on the 6th UICC-TNM classification
✓. No prior treatment of chemotherapy, radiotherapy or surgery against esophageal cancer, except for non-curative resection by EMR/ESD.
✓. Aged 18-75 years
✓. Adequate organ functions
✓. White blood cell (WBC) ≥3×109⁄L
✓. Absolute neutrophil counts (ANC) ≥1.5×109⁄L
✓. Hemoglobin (Hb) ≥10g⁄dl
Exclusion criteria
✕. Esophageal perforation or hematemesis
✕. Synchronous or metachronous malignancies (except for cutaneous (non-melanomas) carcinoma, thyroid papillary carcinoma, phase I seminoma or cervical carcinoma in situ curatively treated and disease free for a minimum of 3 months)
✕. Received thoracic, abdominal or craniocerebral surgery within 30 days
✕. Enrolled in other clinical trials within 30 days